Publications by authors named "Stephanie Beate Geisler"
Article Synopsis
- The study compares the effectiveness of two cancer drugs, letrozole and exemestane, in lowering estrogen levels for postmenopausal women with ER-positive breast cancer.
- Patients participated in an intra-patient cross-over design, first receiving one drug followed by the other, while serum estrogen and drug levels were measured using a sensitive laboratory method.
- Results showed that letrozole was more effective at reducing estrogen levels compared to exemestane, with significant decreases observed after treatment with either drug.
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
Nazli Bahrami Shakila Jabeen Andliena Tahiri Torill Sauer Hilde Presterud Ødegård Stephanie Beate Geisler Jürgen Geisler
Breast Cancer Res Treat
December 2021
Purpose: The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic effects, not necessarily related to estrogen-suppression, may be involved in this well-known "lack of cross-resistance".
Methods: Postmenopausal women with ER positive, HER-2 negative, locally advanced breast cancer were enrolled in the NEOLETEXE-trial and randomized to sequential treatment starting with either letrozole (2.5 mg o.
Article Synopsis
- Letrozole is a competitive aromatase inhibitor, while exemestane is an irreversible aromatase inactivator, leading to different effects on the aromatase enzyme.
- Research shows that exemestane can still be effective after resistance to nonsteroidal aromatase inhibitors like letrozole.
- The NEOLETEXE trial aims to investigate the mechanisms behind this lack of cross-resistance between the two drugs, with ethical approval granted for the study.